Yijun Dong

Yijun Dong

Auto-generated profile, based on publicly available information

Yijun Dong

Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, P. R. China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
XCXi Chen
Xi Chen
Kun ChenKun Chen
Kun Chen
JHJun Hu
Jun Hu
YDYijun Dong
Yijun Dong
MZMenglong Zheng
Menglong Zheng
WZWenzhi Zhang
Wenzhi Zhang
Intervertebral disc degeneration (IDD) is a highly prevalent musculoskeletal disorder affecting millions of adults worldwide, but a poor understanding of its pathogenesis has limited the effectiveness of therapy. In the current study, we integrated untargeted LC/MS metabolomics and magnetic resonance spectroscopy data to investigate metabolic profile alterations during IDD. Combined with validation via a large-cohort analysis, we found excessive lipid droplet accumulation in the nucleus pulposus cells of advanced-stage IDD samples. We also found abnormal palmitic acid (PA) accumulation in IDD nucleus pulposus cells, and PA exposure resulted in lipid droplet accumulation and cell senescence in an endoplasmic reticulum stress-dependent manner. Complementary transcriptome and proteome profiles enabled us to identify solute carrier transporter (SLC) 43A3 involvement in the regulation of the intracellular PA level. SLC43A3 was expressed at low levels and negatively correlated with intracellular lipid content in IDD nucleus pulposus cells. Overexpression of SLC43A3 significantly alleviated PA-induced endoplasmic reticulum stress, lipid droplet accumulation and cell senescence by inhibiting PA uptake. This work provides novel integration analysis-based insight into the metabolic profile alterations in IDD and further reveals new therapeutic targets for IDD treatment.

27 November 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Bispecific antibodies (BsAb) and antibody-drug conjugates (ADC) have shown significant promise in cancer treatment, enhancing drug selectivity and therapeutic efficacy as demonstrated in multiple clinical studies. Bispecific antibody-drug conjugates (BsADC), which combine the targeting capabilities of BsAbs with the cytotoxic potential of ADCs, offer a novel approach to overcoming several challenges associated with ADCs, including limited internalization, off-target toxicity, and drug resistance. In this study, we identified solute carrier family 3 member 2 (SLC3A2) as a highly expressed protein in a variety of solid tumors, making it a promising therapeutic target. We developed a BsAb targeting SLC3A2 and PD-L1 and conjugated it to monomethyl auristatin E (MMAE) to create the SLC3A2/PD-L1 BsADC. The SLC3A2/PD-L1 BsAb effectively blocked PD-1 binding to PD-L1 and activated T cells while also facilitating lysosomal targeting and degradation of poorly internalized PD-L1 antibodies. The SLC3A2/PD-L1 BsADC demonstrated superior antitumor efficacy in PD-L1 low-expressing tumor cells compared with single-target ADCs in both in vitro studies and in multiple xenograft and immunocompetent mouse models. Overall, our engineered SLC3A2/PD-L1 BsADC exhibited enhanced internalization and improved tumor cell targeting, highlighting the potential of lysosome-targeting BsAbs in advancing ADC therapeutic strategies for solid tumors.

12 December 2023 in The FASEB Journal
Verified
Journal Article
Closed access
MXMing Xiong
Ming Xiong
JHJuan‐Juan Hu
Juan‐Juan Hu
MYMeng‐Lin Yao
Meng‐Lin Yao
TSTing‐Ting Song
Ting‐Ting Song
LZLei Zhao
Lei Zhao
HYHui Yang
Hui Yang

4 February 2025
Verified
Other
Open access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Supplementary Figure 4. LC-MS analysis and average DAR value of antibody-drug conjugates. A, LC-MS analysis of SLC3A2/PD-L1 BsADC. LC-MS, liquid chromatography-MS. The average DAR of SLC3A2/PD-L1 BsADC was 0.82. B, LC-MS analysis of SLC3A2 ADC. The average DAR of SLC3A2/PD-L1 BsADC was 1.63. C, LC-MS analysis of PD-L1 ADC. The average DAR of PD-L1 ADC was 0.93.

4 February 2025
Verified
Other
Open access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Supplementary Figure 5. Flow cytometry analysis for apoptosis. A, Flow cytometric analysis for cell apoptosis in SNU-899 cells. B, Flow cytometric analysis for cell apoptosis in H460 cells. C, Flow cytometric analysis for cel

4 February 2025
Verified
Other
Open access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Supplementary Figure 2. Specific targeting of anti-SLC3A2 19G4 mAb and anti-PD-L1 mAb. A, Sequencing results for HeLa SLC3A2KO cells using CRISPR/Cas9 technology. B, Flow cytometry analysis of 19G4 mAb specific binding to SLC3A2 in HeLa-WT and HeLa-SLC3A2KO cell lines. C, Flow cytometry analysis of 2217B3 mAb specific binding to PD-L1 in HeLa-WT and HeLa-PD-L1 cell lines. D, Flow cytometry analysis of 19G4 mAb binding to SLC7A5 and mouse SLC3A2. E, Flow cytometry analysis of 2217B3 mAb binding to PD-1 and mouse PD-L1.